Assessing the wider impact of mtm treatment on transcriptional changes in our PKCα-KR cells revealed a reduction in expression not only of prkcb, but also Sp1 itself and Bcl2, Vegfa, Blnk and Lef1 upon treatment with mtm, compared to no drug control (NDC; Figure 2E), a result similar to that seen in human CLL samples (Supplementary Table S6). Here, PRKCA is linked to B-cell chronic lymphocytic leukemia.